PRISMMEDI.BO up 20.94% to INR 22.58 on BSE : short-term momentum meets valuation check

PRISMMEDI.BO stock jumped 20.94% to INR 22.58 at the BSE close on 20 Feb 2026. The move came on volume of 13,238 shares, nearly three times the average daily flow of 4,916. Intraday range was tight with open, low and high at INR 22.58, signaling aggressive buying at market open. We view this as a short-term momentum burst against mixed fundamentals and limited analyst coverage.

PRISMMEDI.BO stock: price action and market context

The stock closed at INR 22.58, up INR 3.91 from the prior close of INR 18.67. Market cap stands at INR 124,482,177 and shares outstanding equal 6,063,428. The one-day surge lifted the 50-day average of INR 18.21 and the 200-day average of INR 17.16, showing recent outperformance versus the stock’s longer trend.

Volume, volatility and technicals for PRISMMEDI.BO stock

Volume was 13,238, with relative volume near 17.90x, confirming genuine buying interest. Momentum indicators show RSI 56.39 and MACD histogram 0.06, suggesting neutral to mildly bullish momentum. Bollinger middle band sits at INR 17.52 and ATR equals INR 1.48, pointing to moderate intraday volatility.

Fundamentals and valuation snapshot for Prism Medico and Pharmacy Limited (PRISMMEDI.BO)

Reported EPS reads -0.07 and reported PE shows -293.29, reflecting recent accounting or one-off items. Key metrics show book value per share INR 24.89 and PB of 0.82, indicating the market prices the stock below book. Sales and profitability ratios are mixed, with gross margin 38.36% and net margin 26.87% in the latest metrics.

Sector context and risks: Financial Services and small-cap dynamics

Prism Medico and Pharmacy Ltd. is listed on BSE in India but the company profile spans agriculture and pharmaceuticals trading. Small-cap stocks in Financial Services and related conglomerates show higher liquidity risk. Key risks include low analyst coverage, sparse free float, and occasional metric conflicts that can amplify moves.

Meyka AI grade and forecast for PRISMMEDI.BO stock

Meyka AI rates PRISMMEDI.BO with a score out of 100. Meyka AI assigns PRISMMEDI.BO a score 65.20, Grade B, suggestion HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects a yearly price of INR 15.14, below the current INR 22.58. Forecasts are model-based projections and not guarantees.

Trading view and short-term price targets for PRISMMEDI.BO stock

Near-term momentum favors buyers, but liquidity can reverse moves quickly. A pragmatic short-term price target is INR 26.00, implying 15.15% upside from INR 22.58. Use strict stops near INR 18.00 to limit downside. No formal broker price target exists publicly, so traders should size positions carefully.

Final Thoughts

PRISMMEDI.BO stock led small-cap gainers on 20 Feb 2026, rising 20.94% to INR 22.58 on BSE. Volume confirmed the move, but fundamentals remain mixed. Meyka AI’s forecast model projects a yearly price of INR 15.14, implying an implied downside of -32.96% versus today’s close. For short-term traders, a INR 26.00 target offers 15.15% upside, but the stock carries liquidity and reporting risk. Our view frames the rally as momentum-driven, not a verdict on fundamentals. Investors should treat the Meyka grade B (HOLD) and price forecasts as model-based inputs, not guarantees. For detail and quotes, see the company site Prism Medico & Pharmacy Ltd. and market listings on BSE. Meyka AI, an AI-powered market analysis platform, provides these data points for further research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.